Alvogen adds Qsymia to its anti-obesity portfolio in South Korea

6 September 2017

Privately-held US firm Alvogen announced today that it has signed a partnership agreement with Vivus (Nasdaq: VVUS) for the anti-obesity drug Qsymia (phentermine and topiramate extended-release).

Under the terms of the accord, Alvogen will be responsible for regulatory, sales and marketing activities for Qsymia in the Republic of Korea. Qsymia is used for the treatment of chronic weight management or weight-related conditions.

For Alvogen, the agreement will help assert further dominance in the South Korean anti-obesity market, with Qsymia to join a broad portfolio – such as Furimin (phentermine), Furing (phendimetrazine) and Oliet (orlistat) – which are targeted at people with weight-related conditions. Alvogen will seek regulatory approval in Korea for Qsymia ahead of a commercial launch. Providing Qsymia gets the green light, Vivus will receive royalties on Alvogen’s net sales of the drug, in addition to upfront and milestone payments. Further financial terms were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK